|
|
Volumn 2012, Issue , 2012, Pages 129-136
|
|
Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ACUTE DISEASE;
ACUTE LYMPHOBLASTIC LEUKEMIA;
ADOLESCENT;
ADULT;
CHILD;
CLINICAL TRIAL (TOPIC);
DNA METHYLATION;
GENOMICS;
HUMAN;
INFANT;
METHODOLOGY;
ONCOLOGY;
PATHOLOGY;
PRESCHOOL CHILD;
PROBABILITY;
PROGNOSIS;
RECURRENT DISEASE;
REMISSION;
REVIEW;
TIME;
TREATMENT OUTCOME;
ACUTE DISEASE;
ADOLESCENT;
ADULT;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CHILD;
CHILD, PRESCHOOL;
CLINICAL TRIALS AS TOPIC;
DNA METHYLATION;
GENOMICS;
HUMANS;
INFANT;
MEDICAL ONCOLOGY;
PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;
PROBABILITY;
PROGNOSIS;
RECURRENCE;
REMISSION INDUCTION;
TIME FACTORS;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 84872288688
PISSN: None
EISSN: 15204383
Source Type: Journal
DOI: 10.1182/asheducation.v2012.1.129.3800156 Document Type: Review |
|
Times cited : (80)
|
|
References (0)
|
